Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrenkel Topping Regulatory News (FEN)

Share Price Information for Frenkel Topping (FEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 51.60
Bid: 50.00
Ask: 54.00
Change: 0.00 (0.00%)
Spread: 4.00 (8.00%)
Open: 52.00
High: 52.00
Low: 52.00
Prev. Close: 52.00
FEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conclusion of Strategic Review and Trading Update

27 Jun 2017 07:00

RNS Number : 2074J
Frenkel Topping Group PLC
27 June 2017
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

 

27 June 2017

 

Frenkel Topping Group plc

("Frenkel Topping" or the "Group")

 

Conclusion of Strategic Review, Expiration of Offer Period and Trading Update

 

 

Frenkel Topping (AIM: FEN), a specialist independent financial advisor and asset manager focused on asset protection for vulnerable clients, is providing an update on its strategic review announced on 3 April 2017, as well as a trading update for the first six months of the financial year.

 

Overview

 

· The strategic review identified potential acquirers, however the Board believes that none of these proposals appropriately reflected the organic growth potential of the Group, particularly in light of the proposed amendments to the Ogden Discount Rate

· The Board recommits itself to maintaining a progressive dividend policy and accelerating its year-on-year growth in AUM

· Solid H1 trading performance (significant revenue and operating profit progression versus H1 2016), in line with expectations for the full year

· Assets on DFM mandates increased to £290m, and overall AUM to £770m

 

Strategic Review

 

Frenkel Topping has concluded the strategic review announced on 3 April 2017. The Board has decided that it is in the best interest of shareholders, employees and clients to continue as an independent company, pursuing its existing business plan, the prospects for which it believes have been enhanced by proposed amendments to the Ogden Discount Rate, which will materially alter the landscape of the industry.

 

As such, the Group is not in active discussions with any third party in relation to a corporate transaction, such as a merger with or sale of the Company and as such the Formal Sale Process has now been terminated. The Company is therefore no longer in an offer period for the purposes of the Takeover Code and, accordingly, the requirement to make disclosures under Rule 8 of the Code has now ceased.

 

The Board remains enthused by the prospects for the Group and today reaffirms the Group's commitment to deliver attractive on-going value to shareholders, as evidenced by the positive trading for the first six months of this financial year.

 

Trading Update

 

The Group proposes to announce its half year results in early July in which the Board expects to report profit from operations of £1.2m (H1 2016: £0.3m, FY2016 £1.4m) on revenues of £3.7m (H1 2016: £2.8m), as a result of both an increase in Assets Under Management (AUM) to approximately £770m (FY 2016: £745m) (of which approximately £290m will be on a discretionary mandate (FY2016: £253m)) and an increase in gross margin to in excess of 60% (H1 2016: 55%, FY 2016: 58%).

 

In addition, the Group also paid a dividend, increased by 25 per cent. from the previous year, to shareholders in May 2017 and completed the move to a new head office in Manchester.

 

The Board expects this strong growth to continue over the second half of the year and confirms that the Company is trading in line with market expectations, as well as continuing to deliver a progressive dividend policy.

 

Business Plan

 

The Board will continue to execute its existing business plan for the Group. The effects of the Ogden Review are now starting to translate into higher levels of damages available to our clients and this should accelerate the growth of AUM for the Group. In addition to this, the Group expects to increase its market share in the industry, through expanding its London office, increasing the number of authorised individuals employed by the Group and establishing further joint venture relationships with legal firms to drive asset growth.

 

In addition, the Group intends to expand its investment offerings through Frenkel Topping Investment Management and its Safety First product range.

 

As a result of the above, the Board remains fully focused on reaching AUM of £1bn on an organic basis and remains open to opportunistic investments, both to maximise its return on its cash position, as well as other investments and acquisitions that might accelerate the growth of the business and strength of the platform in place.

 

 

Investor enquiries

Jason Granite, Executive Chairman

Richard Fraser, Chief Executive Officer

Julie Dean, Chief Financial Officer

 

+44 (0)161 886 8000

 

finnCap Limited

Adrian Hargrave, James Thompson, Alex Price (Corporate Finance)

Tony Quirke (Corporate Broking)

 

+44 (0)20 7220 0500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGUAUQUPMGQQ
Date   Source Headline
8th May 20247:00 amRNSAnnual Report Posting, Notice of AGM & Dividend
1st May 202410:25 amRNSHolding(s) in Company
23rd Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
22nd Apr 20247:01 amRNSAcquisition
22nd Apr 20247:00 amRNSFinal Results
12th Mar 20247:00 amRNSNotice of Results
20th Feb 20247:00 amRNSDirectorate Change
24th Jan 20247:00 amRNSTrading Update & New Debt Facility
22nd Dec 20238:00 amRNSHolding(s) in Company
13th Nov 20237:00 amRNSPartnership Programme Grows with New Joint Venture
8th Nov 20234:30 pmRNSDirector/PDMR Shareholding
3rd Nov 20238:30 amRNSHolding(s) in Company
3rd Oct 20237:00 amRNSThe Shares and AJ Bell Media investor event
3rd Oct 20237:00 amRNSAppointment of Strategy & Implementation Director
29th Sep 20237:00 amRNSInterim Results
31st Aug 202310:08 amRNSDirector/PDMR Shareholding
29th Aug 20237:00 amRNSDirector Share Purchase
22nd Aug 20237:00 amRNSTrading Update
31st Jul 20237:00 amRNSFEN Announces Joint Venture with Lime Solicitors
21st Jul 20233:20 pmRNSIssue of consideration shares
6th Jul 20237:00 amRNSFEN announces New Major Trauma Centre
20th Jun 20237:00 amRNSDirector/PDMR Shareholding
14th Jun 202312:20 pmRNSResult of AGM
5th Jun 20237:00 amRNSFEN announces New Major Trauma Centre
15th May 20234:15 pmRNSAnnual Report Posting, Notice of AGM & Dividend
24th Apr 20237:00 amRNSFinal Results
22nd Mar 20234:00 pmRNSHolding(s) in Company
15th Mar 202311:47 amRNSDirector/PDMR Shareholding
8th Mar 20237:00 amRNSInvestor Presentation
13th Feb 20237:00 amRNSFrenkel Topping Partnership Programme Grows
7th Feb 20237:00 amRNSTrading Update and Notice of Results
10th Nov 20222:50 pmRNSInterim Dividend Timetable
3rd Nov 20227:00 amRNSFEN to present at AJ Bell investor webinar
24th Oct 20222:30 pmRNSDirector/PDMR Shareholding and Holdings in Company
24th Oct 202212:15 pmRNSHolding(s) in Company
3rd Oct 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
13th Sep 20227:00 amRNSCompletion of Two Acquisitions
31st Aug 20222:15 pmRNSNotice of Results
3rd Aug 202210:17 amRNSHolding(s) in Company
3rd Aug 202210:15 amRNSHolding(s) in Company
29th Jul 202212:15 pmRNSResult of General Meeting
25th Jul 20227:00 amRNSFEN Announces Joint Venture with CFG Law
25th Jul 20227:00 amRNSFEN Announces Joint Venture with CFG Law
12th Jul 202210:50 amRNSHolding(s) in Company
6th Jul 20227:00 amRNSResults of Placing
5th Jul 20222:45 pmRNSProposed Placing to raise approximately £10m
22nd Jun 202211:40 amRNSResult of AGM
16th May 20228:25 amRNSAnnual Report Posting, Notice of AGM & Dividend
4th May 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.